What's in Janssen Infectious Diseases BVBA's pipeline?

Janssen Infectious Diseases BVBA has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Janssen Infectious Diseases BVBA's portfolio?

Top competitors by shared drug class: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Centers for Disease Control and Prevention, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), French National Agency for Research on AIDS and Viral Hepatitis, Germans Trias i Pujol Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/janssen-infectious-diseases-bvba.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Janssen Infectious Diseases BVBA — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Janssen Infectious Diseases BVBA pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Rilpivirine (RPV)	Rilpivirine (RPV)	phase 3	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	Reverse transcriptase	Infectious Diseases

Therapeutic area mix

Infectious Diseases · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 shared drug class
Centers for Disease Control and Prevention · 1 shared drug class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
Germans Trias i Pujol Hospital · 1 shared drug class
International Partnership for Microbicides, Inc. · 1 shared drug class
Janssen-Cilag S.p.A. · 1 shared drug class
Johns Hopkins Bloomberg School of Public Health · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Janssen Infectious Diseases BVBA:

Cite this brief

Drug Landscape (2026). Janssen Infectious Diseases BVBA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-infectious-diseases-bvba. Accessed 2026-05-16.